LNP8701 / Lupin, Kaveri Therapeutics - LARVOL DELTA

A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of LNP8701 (SOS1 inhibitor) in Subjects with Metastatic Solid Tumors (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Clinical • Metastases • P1 data • PK/PD data • Oncology • Solid Tumor

A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors. (ASCO 2026) - "LNP8701 was well tolerated with desirable safety, PK and preliminary efficacy profile."

Clinical • First-in-human • Metastases • P1 data • PK/PD data • Breast Cancer • Cervical Cancer • Colorectal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Thrombocytopenia

Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026 (PRNewswire) - "The abstract reports the findings from an ongoing first-in-human study of LNP8701 in patients with solid tumors....Results indicate that LNP8701 was well tolerated with desirable safety, pharmacokinetics profile and favorable anti-tumor activity. The preliminary efficacy findings demonstrate that two patients completed LNP8701 monotherapy for 12 cycles (i.e., 1 year) and one patient completed 14 cycles with stable disease....Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination."

P1 data • Trial status • Solid Tumor